Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
3.090
-0.130 (-4.04%)
At close: Jul 19, 2024, 4:30 PM
3.080
-0.010 (-0.32%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Sagimet Biosciences Stock Forecast
SGMT's stock price has decreased by -80.75% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Sagimet Biosciences stock have an average target of 35.8, with a low estimate of 6.00 and a high estimate of 67. The average target predicts an increase of 1,058.58% from the current stock price of 3.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SGMT stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $23 → $6 | Hold | Maintains | $23 → $6 | +94.17% | Jul 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +935.60% | Jun 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $48 | Buy | Reiterates | $48 | +1,453.40% | Jun 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +935.60% | Jun 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +935.60% | May 24, 2024 |
Financial Forecast
Revenue This Year
n/a
from 2.00M
Revenue Next Year
n/a
EPS This Year
-1.75
from -2.66
EPS Next Year
-4.09
from -1.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 226.3M |
| Avg | n/a | n/a | n/a | n/a | 95.2M |
| Low | n/a | n/a | n/a | n/a | 13.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.05 | -1.92 | -4.50 | -5.74 | -3.18 |
| Avg | -1.75 | -4.09 | -6.05 | -6.32 | -5.04 |
| Low | -2.11 | -5.58 | -9.19 | -7.08 | -6.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.